alendronate has been researched along with Bone Diseases in 21 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Bone Diseases: Diseases of BONES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this open prospective randomized study was to evaluate the effect of a 6-month treatment with alendronate on the bone mineral density (BMD) at lumbar spine in patients with central diabetes insipidus." | 9.09 | Effect of a short-term treatment with alendronate on bone density and bone markers in patients with central diabetes insipidus. ( Colao, A; Di Somma, C; Faggiano, A; Filippella, M; Klain, M; Lombardi, G; Pivonello, R; Salvatore, M, 1999) |
| "Multiple myeloma is a malignancy of plasma cells with osteolytic bone destruction." | 6.71 | Biphasic anti-osteoclastic action of intravenous alendronate therapy in multiple myeloma bone disease. ( Hamano, T; Kitano, M; Ogata, A; Sano, H; Sekiguchi, M, 2005) |
| "The aim of this open prospective randomized study was to evaluate the effect of a 6-month treatment with alendronate on the bone mineral density (BMD) at lumbar spine in patients with central diabetes insipidus." | 5.09 | Effect of a short-term treatment with alendronate on bone density and bone markers in patients with central diabetes insipidus. ( Colao, A; Di Somma, C; Faggiano, A; Filippella, M; Klain, M; Lombardi, G; Pivonello, R; Salvatore, M, 1999) |
| "Alendronate has been shown to be effective for the treatment of osteoporosis and for reducing the rate of osteoporotic fractures." | 2.71 | The effect of alendronate on bone mineral density in the distal part of the femur and proximal part of the tibia after total knee arthroplasty. ( Chen, HS; Hsu, CC; Huang, CC; Wang, CJ; Wang, JW; Weng, LH, 2003) |
| "Multiple myeloma is a malignancy of plasma cells with osteolytic bone destruction." | 2.71 | Biphasic anti-osteoclastic action of intravenous alendronate therapy in multiple myeloma bone disease. ( Hamano, T; Kitano, M; Ogata, A; Sano, H; Sekiguchi, M, 2005) |
| " These conjugate drugs can be dosed infrequently (weekly or bimonthly) whereas the free drugs must be dosed daily." | 2.58 | Targeting therapeutics to bone by conjugation with bisphosphonates. ( Grynpas, MD; Young, RN, 2018) |
| "Sarcoidosis is a multisystem disease of unknown origin." | 2.47 | Rare localizations of bone sarcoidosis: two case reports and review of the literature. ( Bargagli, E; Bertelli, P; Gonnelli, S; Olivieri, C; Penza, F; Rottoli, P; Volterrani, L, 2011) |
| "To validate our hypothesis that a bisphosphonate (BP) having a nitrogen-containing heterocyclic ring on the side chain, and with no hydroxyl on the geminal carbon would possess increased activity, and better oral bioavailability due to enhanced solubility of its calcium complexes/salts and weaker Ca chelating properties." | 1.30 | Synthesis and preclinical pharmacology of 2-(2-aminopyrimidinio) ethylidene-1,1-bisphosphonic acid betaine (ISA-13-1)-a novel bisphosphonate. ( Alferiev, IS; Breuer, E; Cohen, H; Ezra, A; Golomb, G; Hägele, G; Hoffman, A; Mönkkönen, J; Ornoy, A; Patlas, N; Pinto, T; Sagi, H; Seibel, MJ; Solomon, V; Stepensky, D, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (33.33) | 18.2507 |
| 2000's | 6 (28.57) | 29.6817 |
| 2010's | 5 (23.81) | 24.3611 |
| 2020's | 3 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Barbosa, JS | 1 |
| Almeida Paz, FA | 1 |
| Braga, SS | 1 |
| Haider, IT | 1 |
| Loundagin, LL | 1 |
| Sawatsky, A | 1 |
| Kostenuik, PJ | 1 |
| Boyd, SK | 1 |
| Edwards, WB | 1 |
| Sanchis, P | 1 |
| López-González, ÁA | 1 |
| Costa-Bauzá, A | 1 |
| Busquets-Cortés, C | 1 |
| Riutord, P | 1 |
| Calvo, P | 1 |
| Grases, F | 1 |
| Young, RN | 1 |
| Grynpas, MD | 1 |
| Giannasi, C | 1 |
| Niada, S | 1 |
| Farronato, D | 1 |
| Lombardi, G | 2 |
| Manfredi, B | 1 |
| Farronato, G | 1 |
| Brini, AT | 1 |
| Tournis, S | 1 |
| Dede, AD | 1 |
| Savvidis, C | 1 |
| Triantafyllopoulos, IK | 1 |
| Kattamis, A | 1 |
| Papaioannou, N | 1 |
| Bargagli, E | 1 |
| Olivieri, C | 1 |
| Penza, F | 1 |
| Bertelli, P | 1 |
| Gonnelli, S | 1 |
| Volterrani, L | 1 |
| Rottoli, P | 1 |
| Abediazar, S | 1 |
| Nakhjavani, MR | 1 |
| Ogata, A | 2 |
| Kitano, M | 2 |
| Hashimoto, N | 1 |
| Iwasaki, T | 1 |
| Hamano, T | 2 |
| Kakishita, E | 1 |
| Bereket, A | 1 |
| Erdogan, T | 1 |
| Wang, CJ | 1 |
| Wang, JW | 1 |
| Weng, LH | 1 |
| Hsu, CC | 1 |
| Huang, CC | 1 |
| Chen, HS | 1 |
| Rodan, G | 1 |
| Reszka, A | 1 |
| Golub, E | 1 |
| Rizzoli, R | 1 |
| Sekiguchi, M | 1 |
| Sano, H | 1 |
| Lai, KA | 1 |
| Shen, WJ | 1 |
| Yang, CY | 1 |
| Shao, CJ | 1 |
| Hsu, JT | 1 |
| Lin, RM | 1 |
| Kanis, JA | 1 |
| Gertz, BJ | 1 |
| Singer, F | 1 |
| Ortolani, S | 1 |
| Mian, M | 1 |
| Benetti, D | 1 |
| Aloisi, R | 1 |
| Rosini, S | 1 |
| Fantozzi, R | 1 |
| Rodan, GA | 1 |
| Hirsch, LJ | 1 |
| Adami, S | 1 |
| Yaffe, A | 1 |
| Iztkovich, M | 1 |
| Earon, Y | 1 |
| Alt, I | 1 |
| Lilov, R | 1 |
| Binderman, I | 1 |
| Pivonello, R | 1 |
| Faggiano, A | 1 |
| Di Somma, C | 1 |
| Klain, M | 1 |
| Filippella, M | 1 |
| Salvatore, M | 1 |
| Colao, A | 1 |
| Cohen, H | 1 |
| Alferiev, IS | 1 |
| Mönkkönen, J | 1 |
| Seibel, MJ | 1 |
| Pinto, T | 1 |
| Ezra, A | 1 |
| Solomon, V | 1 |
| Stepensky, D | 1 |
| Sagi, H | 1 |
| Ornoy, A | 1 |
| Patlas, N | 1 |
| Hägele, G | 1 |
| Hoffman, A | 1 |
| Breuer, E | 1 |
| Golomb, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Efficacy of Denosumab in Decreasing Periprosthetic Bone Loss in Patients With Total Knee Arthroplasty: A Randomised, Double Blind, Placebo Controlled Clinical Trial[NCT02760979] | Phase 4 | 60 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
| Alendronate in the Prevention of Collapse of Femoral Head in Non-Traumatic Osteonecrosis[NCT00265252] | Phase 4 | 60 participants | Interventional | 2005-06-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for alendronate and Bone Diseases
| Article | Year |
|---|---|
Bisphosphonates, Old Friends of Bones and New Trends in Clinics.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Drug Compo | 2021 |
Targeting therapeutics to bone by conjugation with bisphosphonates.
Topics: Alendronate; Animals; Bone and Bones; Bone Diseases; Delayed-Action Preparations; Diphosphonates; Dr | 2018 |
Rare localizations of bone sarcoidosis: two case reports and review of the literature.
Topics: Alendronate; Bone Diseases; Bone Neoplasms; Diagnosis, Differential; Drug Therapy, Combination; Fema | 2011 |
Bone safety of long-term bisphosphonate treatment.
Topics: Alendronate; Bone and Bones; Bone Diseases; Bone Remodeling; Calcification, Physiologic; Diphosphona | 2004 |
Rationale for the use of alendronate in osteoporosis.
Topics: Alendronate; Bone Diseases; Bone Remodeling; Diphosphonates; Humans; Osteoporosis | 1995 |
Bisphosphonates in prostate carcinoma.
Topics: Alendronate; Biomarkers; Bone Diseases; Bone Neoplasms; Bone Resorption; Clinical Trials as Topic; C | 1997 |
4 trials available for alendronate and Bone Diseases
| Article | Year |
|---|---|
The effect of alendronate on bone mineral density in the distal part of the femur and proximal part of the tibia after total knee arthroplasty.
Topics: Absorptiometry, Photon; Aged; Alendronate; Arthroplasty, Replacement, Knee; Bone Density; Bone Disea | 2003 |
Biphasic anti-osteoclastic action of intravenous alendronate therapy in multiple myeloma bone disease.
Topics: Adult; Aged; Alendronate; Anesthetics, Intravenous; beta 2-Microglobulin; Biomarkers, Tumor; Bone Di | 2005 |
The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study.
Topics: Adult; Aged; Alendronate; Bone Diseases; Diphosphonates; Disease Progression; Female; Femur Head Nec | 2005 |
Effect of a short-term treatment with alendronate on bone density and bone markers in patients with central diabetes insipidus.
Topics: Adolescent; Adult; Alendronate; Bone and Bones; Bone Density; Bone Diseases; Collagen; Collagen Type | 1999 |
11 other studies available for alendronate and Bone Diseases
| Article | Year |
|---|---|
Twelve Months of Denosumab and/or Alendronate Is Associated With Improved Bone Fatigue Life, Microarchitecture, and Density in Ovariectomized Cynomolgus Monkeys.
Topics: Alendronate; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Diseases; | 2023 |
Understanding the Protective Effect of Phytate in Bone Decalcification Related-Diseases.
Topics: Absorptiometry, Photon; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases; | 2021 |
Nitrogen Containing Bisphosphonates Impair the Release of Bone Homeostasis Mediators and Matrix Production by Human Primary Pre-Osteoblasts.
Topics: Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density Conservation Agents; Bone Diseases; Calc | 2019 |
Effects of teriparatide retreatment in a patient with β-thalassemia major.
Topics: Adult; Alendronate; beta-Thalassemia; Bone Density Conservation Agents; Bone Diseases; Humans; Male; | 2015 |
Effect of alendronate on early bone loss of renal transplant recipients.
Topics: Adult; Alendronate; Body Mass Index; Bone and Bones; Bone Density; Bone Density Conservation Agents; | 2011 |
Chemotherapy did not enhance the anti-osteolytic effects of bisphosphonate in multiple myeloma bone disease.
Topics: Adult; Alendronate; Biomarkers; Bone Diseases; Drug Therapy, Combination; Female; Humans; Multiple M | 2002 |
Oral bisphosphonate therapy for vitamin D intoxication of the infant.
Topics: Administration, Oral; Alendronate; Bone Diseases; Hand; Humans; Hypercalcemia; Iatrogenic Disease; I | 2003 |
Effects of bisphosphonate derivatives on macrophage function.
Topics: Alendronate; Animals; Bone Diseases; Clodronic Acid; Diphosphonates; Glucuronidase; Lysosomes; Macro | 1994 |
Treatment of bone in elderly subjects: calcium, vitamin D, fluor, bisphosphonates, calcitonin.
Topics: Aged; Alendronate; Animals; Bone Diseases; Diphosphonates; Humans | 1996 |
Local delivery of an amino bisphosphonate prevents the resorptive phase of alveolar bone following mucoperiosteal flap surgery in rats.
Topics: Administration, Topical; Alendronate; Alveolar Bone Loss; Alveolar Process; Animals; Bone Diseases; | 1997 |
Synthesis and preclinical pharmacology of 2-(2-aminopyrimidinio) ethylidene-1,1-bisphosphonic acid betaine (ISA-13-1)-a novel bisphosphonate.
Topics: Administration, Oral; Alendronate; Animals; Antineoplastic Agents; Betaine; Bone Diseases; Bone Neop | 1999 |